Stock Detail
Videos
ChromaDex Corp. (CDXC) Company Webcast
This company webcast features ChromaDex Corp. (Nasdaq: CDXC). ChromaDex is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. This company webcast was recorded during the Lytham Partners 2025 Investor...
ChromaDex Corporation (CDXC) Fireside Chat
During this fireside chat Ben Shamsian, Vice President, Lytham Partners and Sean McGowan, Roth Capital Partners, chat with Rob Fried, Chief Executive Officer of ChromaDex Corporation. ChromaDex (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide...
News
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder
Results demonstrated that nicotinamide riboside (NR) significantly elevated NAD+ levels and improved multiple clinical markers in people with Werner Syndrome Niagen Bioscience expands rare disease research portfolio, supporting further investigation of NAD+...
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference
LOS ANGELES - Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief...
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. LOS ANGELES - Niagen...